Active substance
Results for the substance darunavir+cobicistat+emtricitabine+tenofovir alafenamide
1 result
About this active substance
The combination of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide is used in the treatment of human immunodeficiency virus (HIV-1) infection. This is a combination antiretroviral therapy that helps suppress HIV replication, reducing viral load and maintaining immune system function. It is indicated for adults and adolescents aged 12 years and older who weigh at least 40 kg.
- Darunavir is a protease inhibitor that blocks the HIV protease enzyme, which is essential for processing viral proteins needed for virus replication. By inhibiting this enzyme, darunavir prevents the formation of mature, infectious viral particles.
- Cobicistat is a pharmacokinetic enhancer that has no direct antiviral activity but increases the blood concentration of darunavir by inhibiting liver enzymes responsible for its metabolism. This enhances the effectiveness of the treatment.
- Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the HIV reverse transcriptase enzyme, which is essential for viral replication. They prevent the integration of viral genetic material into host cells, thereby reducing virus replication.
This combination is administered as a single tablet, taken once daily, which simplifies adherence to treatment. It is important for patients to take the medication with food to ensure optimal absorption.
While effective, this combination may cause side effects. The most common include nausea, diarrhea, headache, fatigue, and skin rash. In rare cases, more serious reactions such as liver dysfunction, kidney failure, or decreased bone mineral density may occur. Regular monitoring of liver and kidney function, as well as overall health, is essential for patients on this therapy.
- Darunavir is a protease inhibitor that blocks the HIV protease enzyme, which is essential for processing viral proteins needed for virus replication. By inhibiting this enzyme, darunavir prevents the formation of mature, infectious viral particles.
- Cobicistat is a pharmacokinetic enhancer that has no direct antiviral activity but increases the blood concentration of darunavir by inhibiting liver enzymes responsible for its metabolism. This enhances the effectiveness of the treatment.
- Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the HIV reverse transcriptase enzyme, which is essential for viral replication. They prevent the integration of viral genetic material into host cells, thereby reducing virus replication.
This combination is administered as a single tablet, taken once daily, which simplifies adherence to treatment. It is important for patients to take the medication with food to ensure optimal absorption.
While effective, this combination may cause side effects. The most common include nausea, diarrhea, headache, fatigue, and skin rash. In rare cases, more serious reactions such as liver dysfunction, kidney failure, or decreased bone mineral density may occur. Regular monitoring of liver and kidney function, as well as overall health, is essential for patients on this therapy.